Editor's note: SNMMI and the European Association of Nuclear Medicine periodically define
new standards/guidelines for nuclear medicine practice to help advance the science of …

The use of recombinant human thyrotropin (rhTSH) testing in the diagnosis and therapy of
differentiated thyroid cancer (DTC) has been adopted over the last two decades as an …

ABSTRACT Introduction Differentiated thyroid carcinomas (DTCs) are treated with (near-)
total thyroidectomy and radioiodine therapy. Recently, the use of highly sensitive …

Abstract Objective According to the 2015 American Thyroid Association (ATA) guidelines,
thyroid ablation by iodine-131 (I-131) therapy is absolutely recommended only in patients …

Background: Patients with excellent response to initial therapy have a low rate of tumor
recurrence. The objectives of this study were to evaluate the rate of early tumor recurrence in …

The dedifferentiation of differentiated thyroid cancer (DTC) is a challenging problem for
radioactive iodine (131I) treatment, also known as radioiodine refractory differentiated …

Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its
median survival rate remains poor because of its resistance to conventional therapy …

Radiotheragnostics represents the systematic integration of diagnostic imaging and
therapeutics using radionuclides targeting specific characteristics of tumor biology …

Objective: The prevalence of undetectable pre-ablation stimulated thyroglobulin (s-Tg) and
its clinical implications in high-risk papillary thyroid cancer (PTC) patients remain poorly …

Background: The current management of papillary thyroid micro carcinoma (PTMC) has
become more conservative. However, high-risk characteristics that can only be revealed …